Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis

Summary

This study is intended to treat ankylosing spondylitis (AS). AS is a form of arthritis that primarily affects the spine. It is characterized by inflammation of the spinal joints that can lead to severe pain, and in more advanced cases, ankylosis (sections of the spine fuse in a fixed, immobile position). The study will be an ascending single and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous KIN-1901 in healthy subjects and subjects with AS.

Timeline

Start

2019-11-12

Primary completion

2020-04-07

Completion

2020-04-07

Drugs

Indications